ArticleBioengineering (Basel, Switzerland)2024
The Origins of Engineered Biomaterials: NSF-Funded, University of Washington Engineered Biomaterials (UWEB).
Article in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Commemorative 10th Anniversary Issue ofBioengineering (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The University of Washington Engineered Biomaterials (UWEB) Engineering Research Center (ERC) was funded from 1996 to 2007 by the U.S. National Science Foundation. The mission of UWEB was to advance biomaterials by integrating modern biology with materials science. UWEB specifically focused on the healing and integration of medical implants. UWEB teamed biologists, physicians, engineers, and industry and demonstrated three paths that might advance biomaterials so they could seamlessly integrate and heal in the body. The three primary lines of investigation were precision porous scaffolds, super-non-fouling surfaces, and the control of matricellular proteins. The UWEB program set the groundwork for the modern field of immunoengineering. Also, UWEB invested significantly in training scientists/engineers who could freely integrate advances in biological sciences, state-of-the-art materials science, and medical technology. This historical summary of the UWEB program demonstrates that federal investment in interfacing forefront fields can yield dividends with benefits for society and the economy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.